Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Fiche publication
Date publication
juillet 2020
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LIPSKER Dan
Tous les auteurs :
Reymann V, Bessis D, Bergeret B, Lipsker D, Du-Thanh A, Terrail N, Dandurand M, Dereure O
Lien Pubmed
Résumé
Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treated with low-dose LND in three institutional Departments of Dermatology was conducted to further assess the benefit/risk ratio of this molecule in this setting (Institutional Review Board for ethical issues of University Hospital of Montpellier 2018_IRB-MTP_11-01). Primary endpoints were best overall response (BOR) obtained with initial dosage or after dose adjustment and time to achieve BOR.
Mots clés
cutaneous lupus erythematosus, lenalidomide, neuropathy, refractory
Référence
J Eur Acad Dermatol Venereol. 2020 Jul 30;: